Dr. Aytekin Oto is Professor of Radiology and Surgery, Dean for Clinical Affairs, head of the Faculty Practice Plan and Chief Physician at the University of Chicago. Dr. Oto has a wide range of experience and expertise in the imaging of diseases affecting abdomen and pelvis. His research interest focus is development and clinical application of novel prostate MRI acquisition and interpretation so as to facilitate and improve the efficiency of prostate cancer and develop image guided prostate therapy options for the appropriate patients diagnosed with prostate cancer. His research has resulted in more than 250 publications and over 150 scientific exhibits at national and international meetings. The two overarching aims of his research are “non-invasive and accurate diagnosis of aggressive prostate cancer using MR imaging“ and “eradication of localized prostate cancer with minimal complications using minimally invasive treatment methods”. His group has developed new quantitative MR acquisition and interpretation techniques such Hybrid Multi-dimensional MRI and tested MR guided therapy methods such as laser and focused ultrasound ablation in clinical and pre-clinical studies. He has several industry, foundation and NIH grants and serves at the Editorial Board of Radiology. Dr. Oto received numerous awards including AIMBE fellowship, Distinguished Investigator Award, RSNA honored educator award and Distinguished Senior Clinician Award.
Cleveland Clinic Foundation
Cleveland, Ohio
- Abdominal Imaging Fellowship
1998
Hacettepe University
Ankara, Turkey
- Diagnostic Radiology
1997
Hacettepe University
Ankara, Turkey
MD - Medical School
1993
Implementation of a high-resolution, high-contrast magnetic resonance imaging protocol with extended delayed phases for peritoneal mesothelioma.
Implementation of a high-resolution, high-contrast magnetic resonance imaging protocol with extended delayed phases for peritoneal mesothelioma. Quant Imaging Med Surg. 2024 Mar 15; 14(3):2580-2589.
PMID: 38545076
Self-supervised multicontrast super-resolution for diffusion-weighted prostate MRI.
Self-supervised multicontrast super-resolution for diffusion-weighted prostate MRI. Magn Reson Med. 2024 Feb 02.
PMID: 38308149
Prostate Cancers Invisible on Multiparametric MRI: Pathologic Features in Correlation with Whole-Mount Prostatectomy.
Prostate Cancers Invisible on Multiparametric MRI: Pathologic Features in Correlation with Whole-Mount Prostatectomy. Cancers (Basel). 2023 Dec 13; 15(24).
PMID: 38136370
Multi-model sequential analysis of MRI data for microstructure prediction in heterogeneous tissue.
Multi-model sequential analysis of MRI data for microstructure prediction in heterogeneous tissue. Sci Rep. 2023 10 01; 13(1):16486.
PMID: 37779137
Four-quadrant vector mapping of hybrid multidimensional MRI data for the diagnosis of prostate cancer.
Four-quadrant vector mapping of hybrid multidimensional MRI data for the diagnosis of prostate cancer. Med Phys. 2024 Mar; 51(3):2057-2065.
PMID: 37642562
Parametric maps of spatial two-tissue compartment model for prostate dynamic contrast enhanced MRI - comparison with the standard tofts model in the diagnosis of prostate cancer.
Parametric maps of spatial two-tissue compartment model for prostate dynamic contrast enhanced MRI - comparison with the standard tofts model in the diagnosis of prostate cancer. Phys Eng Sci Med. 2023 Sep; 46(3):1215-1226.
PMID: 37432557
Improving reader accuracy and specificity with the addition of hybrid multidimensional-MRI to multiparametric-MRI in diagnosing clinically significant prostate cancers.
Improving reader accuracy and specificity with the addition of hybrid multidimensional-MRI to multiparametric-MRI in diagnosing clinically significant prostate cancers. Abdom Radiol (NY). 2023 10; 48(10):3216-3228.
PMID: 37358605
ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update.
ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update. J Am Coll Radiol. 2023 05; 20(5S):S187-S210.
PMID: 37236742
An Interactive App with Multi-parametric MRI - Whole-Mount Histology Correlation for Enhanced Prostate MRI Training of Radiology Residents.
An Interactive App with Multi-parametric MRI - Whole-Mount Histology Correlation for Enhanced Prostate MRI Training of Radiology Residents. Acad Radiol. 2023 09; 30 Suppl 1:S21-S29.
PMID: 37137744
ACR Appropriateness Criteria® Post-Treatment Follow-up of Prostate Cancer: 2022 Update.
ACR Appropriateness Criteria® Post-Treatment Follow-up of Prostate Cancer: 2022 Update. J Am Coll Radiol. 2023 05; 20(5S):S164-S186.
PMID: 37236741